大疱性类天疱疮瘙痒相关机制的研究进展

doi:10.35541/cjd.20210448

Abstract

Abstract: 【Abstract】 Pruritus is one of the typical clinical manifestations of bullous pemphigoid （BP）. In recent years, researchers have gradually recognized that the histamine-independent itch pathway plays an important role in BP. Eosinophils, basophils, interleukin （IL）-31, IL-4, IL-13, thymic stromal lymphopoietin, periostin and substance P are all closely related to the occurrence of pruritus in BP. This review mainly elaborates research progress in mechanisms related to pruritus in BP.

Key words: Pemphigoid, bullous, Pruritus, Interleukin-4, Eosinophils, Basophils, Interleukin-31

Kailibinuer·Abulikemu, Liang Junqin. Mechanisms of pruritus in bullous pemphigoid[J]. Chinese Journal of Dermatology, 2022, 55(10): 919-921.doi:10.35541/cjd.20210448

References ［28］

［1］	Ben Mordehai Y, Faibish H, Astman N, et al. Characteristics of patients with bullous pemphigoid: comparison of classic bullous pemphigoid to non⁃bullous pemphigoid［J］. J Eur Acad Dermatol Venereol, 2020,34（1）:161⁃165. doi: 10.1111/jdv.15883.
［2］	Briand C, Gourier G, Poizeau F, et al. Characteristics of pruritus in bullous pemphigoid and impact on quality of life: a prospective cohort study［J］. Acta Derm Venereol, 2020,100（18）:adv00320. doi: 10.2340/00015555⁃3683.
［3］	Hashimoto T, Kursewicz CD, Fayne RA, et al. Pathophysiologic mechanisms of itch in bullous pemphigoid［J］. J Am Acad Dermatol, 2020,83（1）:53⁃62. doi: 10.1016/j.jaad.2019.07.060.
［4］	Ständer S, Hammers CM, Vorobyev A, et al. The impact of lesional inflammatory cellular infiltrate on the phenotype of bullous pemphigoid［J］. J Eur Acad Dermatol Venereol, 2021,35（8）:1702⁃1711. doi: 10.1111/jdv.17303.
［5］	de Graauw E, Sitaru C, Horn M, et al. Evidence for a role of eosinophils in blister formation in bullous pemphigoid［J］. Allergy, 2017,72（7）:1105⁃1113. doi: 10.1111/all.13131.
［6］	Simon D, Yousefi S, Cazzaniga S, et al. Mepolizumab failed to affect bullous pemphigoid: a randomized, placebo⁃controlled, double⁃blind phase 2 pilot study［J］. Allergy, 2020,75（3）:669⁃672. doi: 10.1111/all.13950.
［7］	Astra Zeneca. A study to investigate the use of benralizumab in patients with bullous pemphigoid［EB/OL］.［2021⁃06⁃11］. https://clinicaltrials.gov/ct2/show/NCT04612790.
［8］	Barrios DM, Phillips GS, Geisler AN, et al. IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti⁃HER2 therapies［J］. Ann Oncol, 2021,32（6）:736⁃745. doi: 10.1016/j.annonc.2021.02.016.
［9］	Seyed Jafari SM, Gadaldi K, Feldmeyer L, et al. Effects of omalizumab on FcεRI and IgE expression in lesional skin of bullous pemphigoid［J］. Front Immunol, 2019,10:1919. doi: 10.3389/fimmu.2019.01919.
［10］	Seyed Jafari SM, Feldmeyer L, Bossart S, et al. Case report: combination of omalizumab and dupilumab for recalcitrant bullous pemphigoid［J］. Front Immunol, 2020,11:611549. doi: 10.3389/fimmu.2020.611549.
［11］	Wang F, Trier AM, Li F, et al. A basophil⁃neuronal axis promotes itch［J］. Cell, 2021,184（2）:422⁃440.e17. doi: 10.1016/j.cell.2020.12.033.
［12］	Rüdrich U, Gehring M, Papakonstantinou E, et al. Eosinophils are a major source of interleukin⁃31 in bullous pemphigoid［J］. Acta Derm Venereol, 2018,98（8）:766⁃771. doi: 10.2340/00015 555⁃2951.
［13］	Raap U, Gehring M, Kleiner S, et al. Human basophils are a source of ⁃ and are differentially activated by ⁃ IL⁃31［J］. Clin Exp Allergy, 2017,47（4）:499⁃508. doi: 10.1111/cea.12875.
［14］	Maglie R, Ugolini F, De Logu F, et al. Overexpression of helper T cell type 2⁃related molecules in the skin of patients with eosinophilic dermatosis of hematologic malignancy［J］. J Am Acad Dermatol, 2021,doi: 10.1016/j.jaad.2021.07.007.
［15］	Egeberg A, Thyssen JP, Wu JJ. Anti⁃interleukin⁃31 receptor a antibody for atopic dermatitis［J］. N Engl J Med, 2017,376（21）:2092⁃2093. doi: 10.1056/NEJMc1704013.
［16］	Kabashima K, Matsumura T, Komazaki H, et al. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus［J］. N Engl J Med, 2020,383（2）:141⁃150. doi: 10.1056/NEJMoa1917006.
［17］	Ständer S, Yosipovitch G, Legat FJ, et al. Trial of nemolizumab in moderate⁃to⁃severe prurigo nodularis［J］. N Engl J Med, 2020,382（8）:706⁃716. doi: 10.1056/NEJMoa1908316.
［18］	Campion M, Smith L, Gatault S, et al. Interleukin⁃4 and interleukin⁃13 evoke scratching behaviour in mice［J］. Exp Dermatol, 2019,28（12）:1501⁃1504. doi: 10.1111/exd.14034.
［19］	Abdat R, Waldman RA, de Bedout V, et al. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series［J］. J Am Acad Dermatol, 2020,83（1）:46⁃52. doi: 10.1016/j.jaad. 2020.01.089.
［20］	杨璐, 曾跃平, 晋红中. 度普利尤单抗联合糖皮质激素治疗大疱性类天疱疮:国内首报并文献复习［J］. 中华临床免疫和变态反应杂志, 2021,15（1）:47⁃52. doi: 10.3969/j.issn.1673⁃8705. 2021.01.009.
［21］	Kaye A, Gordon SC, Deverapalli SC, et al. Dupilumab for the treatment of recalcitrant bullous pemphigoid［J］. JAMA Dermatol, 2018,154（10）:1225⁃1226. doi: 10.1001/jamadermatol.2018.2526.
［22］	Regeneron Pharmaceuticals. A study to evaluate the efficacy and safety of dupilumab in adult patients with bullous pemphigoid （LIBERTY⁃BP）［EB/OL］.［2021⁃06⁃11］. https://www.ncbi.nlm.nih.gov/search/all/?term=NCT04206553.
［23］	Li SZ, Jin XX, Ge XL, et al. Thymic stromal lymphopoietin is implicated in the pathogenesis of bullous pemphigoid by dendritic cells［J］. J Immunol Res, 2020,2020:4594630. doi: 10.1155/2020/4594630.
［24］	Mishra SK, Wheeler JJ, Pitake S, et al. Periostin activation of integrin receptors on sensory neurons induces allergic itch［J］. Cell Rep, 2020,31（1）:107472. doi: 10.1016/j.celrep.2020.03.036.
［25］	Mitamura Y, Nunomura S, Nanri Y, et al. The IL⁃13/periostin/IL⁃24 pathway causes epidermal barrier dysfunction in allergic skin inflammation［J］. Allergy, 2018,73（9）:1881⁃1891. doi: 10.1111/all.13437.
［26］	Yosipovitch G, Ständer S, Kerby MB, et al. Serlopitant for the treatment of chronic pruritus: results of a randomized, multicenter, placebo⁃controlled phase 2 clinical trial［J］. J Am Acad Dermatol, 2018,78（5）:882⁃891.e10. doi: 10.1016/j.jaad. 2018.02.030.
［27］	Ständer S, Kwon P, Hirman J, et al. Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo⁃controlled trial［J］. J Am Acad Dermatol, 2019,80（5）:1395⁃1402. doi: 10.1016/j.jaad.2019.01.052.
［28］	Pariser DM, Bagel J, Lebwohl M, et al. Serlopitant for psoriatic pruritus: a phase 2 randomized, double⁃blind, placebo⁃controlled clinical trial［J］. J Am Acad Dermatol, 2020,82（6）:1314⁃1320. doi: 10.1016/j.jaad.2020.01.056.

[1]	Zheng Jiayuan, Yu Bingqian, Chen Xianxia, Luo Zhicheng. Characteristics of pruritus in adult patients with psoriasis vulgaris and its effect on quality of life [J]. Chinese Journal of Dermatology, 2022, 55(9): 790-794.
[2]	Fan Birao, Chen Xixue, Wang Mingyue. Retrospective analysis of efficacy and safety of minocycline alone or in combination with low-dose glucocorticoids in the treatment of 15 cases of pemphigus erythematosus and 9 cases of pemphigus herpetiformis [J]. Chinese Journal of Dermatology, 2022, 55(8): 676-681.
[3]	Working Group for Atopic Dermatitis, Chinese Society of Dermatology, Working Group for Children′s Diseases, Chinese Society of Dermatology. Treatment of atopic dermatitis with dupilumab: an expert consensus [J]. Chinese Journal of Dermatology, 2022, 55(6): 465-470.
[4]	Zhao Liuqi, Chen Yan, Chen Danyang, Fan Birao, Wang Rui, Shang Panpan, Chen Xixue, Zhu Xuejun, Wang Mingyue. Efficacy and safety of dupilumab in the treatment of 21 cases of bullous pemphigoid: a retrospective study [J]. Chinese Journal of Dermatology, 2022, 55(6): 480-485.
[5]	Wen Guangdong, Mao Dandan, Zhang Yuanyuan, Dou Yuanqing, Zhao Pei, Wu Chenyu, Zhang Jianzhong. A case of generalized lichen amyloidosis treated with dupilumab: the first case reported in China [J]. Chinese Journal of Dermatology, 2022, 55(6): 508-510.
[6]	Liu Bo, Song Xiaoting, Li Ruoyu, Zhao Zuotao. Clinical efficacy and safety of dupilumab in the treatment of atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 295-298.
[7]	Wang Ao, Yao Xu. Mechanisms of pruritus in atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 357-361.
[8]	Group on Medical Aesthetics and Cosmetology, Chinese Academy of Aesthetic Medicine. Management of scalp health: a Chinese expert consensus statement （2022） [J]. Chinese Journal of Dermatology, 2022, 55(10): 843-849.
[9]	Cheng Bihong, Dou Xia. Diagnosis and classification of chronic prurigo [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210130-e20210130.
[10]	Committee on Allergic Diseases, China Dermatologist Association, Atopic Dermatitis Research Center, Chinese Society of Dermatology, Dermatology Branch of China International Exchange and Promotion Association for Medical and Healthcare. Expert consensus for management of itch in atopic dermatitis [J]. Chinese Journal of Dermatology, 2021, 54(5): 391-396.
[11]	Song Zhiqiang, Wang Huan. Advances in the treatment of atopic dermatitis: new medications, new methods and new models [J]. Chinese Journal of Dermatology, 2021, 54(2): 161-164.
[12]	Deng Sisi, Wang Huan, Ge Lan, Song Zhiqiang. Clinical features of atopic dermatitis and evaluation of its diagnostic criteria: a retrospective analysis of 165 inpatients with atopic dermatitis from 2000 to 2020 [J]. Chinese Journal of Dermatology, 2021, 54(12): 1077-1081.
[13]	Yu Miao, Zhang Jing, Chen Yudi, Liu Bo, Song Xiaoting, Liu Jing, Zhang Xue, Zhao Zuotao. Evaluation of reliability, validity and sensitivity of the Chinese version of pruritus-specific quality of life instrument [J]. Chinese Journal of Dermatology, 2020, 53(9): 698-703.
[14]	Xiang Ruiyu, Li Suo, Feng Suying. Application of pregabalin in dermatology [J]. Chinese Journal of Dermatology, 2020, 53(3): 233-235.
[15]	Gao Xiaoman, Li Ming, Yang Min, Wen Wei, Sun Kailyu, Chang Jianmin, Fu Yu. Clinical analysis of vulvar lichen simplex chronicus [J]. Chinese Journal of Dermatology, 2020, 53(2): 113-116.

Mechanisms of pruritus in bullous pemphigoid

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［28］

Related Articles 15

Metrics

Comments

Recommended 10